Asthma Control and Patient Satisfaction Among Early Pediatric Users of Montelukast

REFERENCES

• Guidelines for the Diagnosis and Management of Asthma: Expert Panel Report 2. NIH Publication No. 97-4051; National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD 1997
   Google Scholar
• Li J.T., Pearlman D.S., Nicklas R.A., Lowenthal M., Rosenthal R.R., Bernstein I.L., Berger W.E., Dykewicz M.S., Fineman S., Lee R.E., Portnoy J.M., Spector S.L. Algorithm for the Diagnosis and Management of Asthma: A Practice Parameter Update: Joint Task Force on Practice Parameters, Representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Ann. Allergy Asthma Immunol. 1998; 1(5 pt. 1)415–420
   Google Scholar
• Lipworth B.J. Systemic Adverse Effects of Inhaled Corticosteroid Therapy: A Systematic Review and Meta-analysis. Arch. Intern. Med. 1999; 159(9)941–955
   PubMed Web of Science ®Google Scholar
• Agertoft L., Pedersen S. Effect of Long-Term Treatment with Inhaled Budesonide on Adult Height in Children with Asthma. N. Engl. J. Med. 2000; 343(15)1064–1069
   PubMed Web of Science ®Google Scholar
• The Childhood Asthma Management Program Research Group. Long-Term Effects of Budesonide or Nedocromil in Children with Asthma. N. Engl. J. Med. 2000; 343(15)1054–1063
   PubMed Web of Science ®Google Scholar
• Garbe E., LeLorier J., Boivin J.F., Suissa S. Inhaled and Nasal Glucocorticoids and the Risks of Ocular Hypertension or Open-Angle Glaucoma. JAMA 1997; 277(9)722–727
   PubMed Web of Science ®Google Scholar
• Kelloway J.S., Wyatt R.A., Adlis S.A. Comparison of Patients’ Compliance with Prescribed Oral and Inhaled Asthma Medications. Arch. Intern. Med. 1994; 154(12)1349–1352
   PubMed Web of Science ®Google Scholar
• Wenzel S.E. Antileukotriene Drugs in the Management of Asthma. JAMA 1998; 280(24)2068–2069
   Google Scholar
• Global Strategy for Asthma Management and Prevention: NHLBI/WHO Workshop Report (Revised), 1998
   Google Scholar
• HEDIS 2000. Vol. 2. Technical Specifications. National Committee for Quality Assurance, Washington, DC 1999
   Google Scholar
• Jarvis B., Markham A. Montelukast: A Review of Its Therapeutic Potential in Persistent Asthma. Drugs 2000; 59(4)891–928
   Google Scholar
• Barnes N.C., Miller C.J. Effect of Leukotriene Receptor Antagonist Therapy on the Risk of Asthma Exacerbations in Patients with Mild to Moderate Asthma: An Integrated Analysis of Zafirlukast Trials. Thorax 2000; 55: 478–483
   PubMed Web of Science ®Google Scholar
• Reiss T.F., Chervinsky P., Dockhorn R.J., Shingo S., Seidenberg B., Edwards T.B. Montelukast, a Once-Daily Leukotriene Receptor Antagonist, in the Treatment of Chronic Asthma: A Multicenter, andomized, ouble-Blind Trial. Montelukast Clinical Research Study Group. Arch. Intern. Med. 1998; 158(11)1213–1220
   PubMed Web of Science ®Google Scholar
• Greening A.P., Ind P.W., Northfield M., Shaw G. Added Salmeterol Versus Higher-Dose Corticosteroid in Asthma Patients with Symptoms on Existing Inhaled Corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344(8917)219–224
   PubMed Web of Science ®Google Scholar
• Lofdahl C.G., Reiss T.F., Leff J.A., Israel E., Noonan M.J., Finn A.F., Seidenberg B.C., Capizzi T., Kundu S., Godard P. Randomised, lacebo Controlled Trial of Effect of a Leukotriene Receptor Antagonist, ontelukast, on Tapering Inhaled Corticosteroids in Asthmatic Patients. BMJ 1999; 319(7202)87–90
   PubMed Web of Science ®Google Scholar
• Laviolette M., Malmstrom K., Lu S., Chervinsky P., Pujet J.C., Peszek I., Zhang J., Reiss T.F. Montelukast Added to Inhaled Beclamethasone in Treatment of Asthma. Am. J. Respir. Care Med. 1999; 160(6)1862–1868
   PubMed Web of Science ®Google Scholar
• Tamaoki J., Kondo M., Sakai N., Nakata J., Takemura H., Nagai A., Takizawa T., Konno K. Leukotriene Antagonist Prevents Exacerbation of Asthma During Reduction of High-Dose Inhaled Corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am. J. Respir. Crit. Care Med. 1997; 155(4)1235–1240
   Google Scholar
• Dahlen B., Nizankowska E., Szczeklik A., Zetterstrom O., Bochenek G., Kumlin M., Mastalerz L., Pinis G., Swanson L.J., Boodhoo T.I., Wright S., Dube L.M., Dahlen S.E. Benefits from Adding the 5-Lipoxygenase Inhibitor Zileuton to Conventional Therapy in Aspirin-Intolerant Asthmatics. Am. J. Respir. Crit. Care Med. 1998; 157(4 pt. 1)1187–1194
   PubMed Web of Science ®Google Scholar
• Price D. Tolerability of Montelukast. Drugs 2000; 59(Suppl. 1)35–42
   Google Scholar
• Vollmer W.M., Markson L., O’Connor E., Sanocki L.L., Fitterman L., Berger M., Buist A.S. Association of Asthma Control with Health Care Utilization and Quality of Life. Am. J. Respir. Crit. Care Med. 1999; 160(5)1647–1652
   PubMed Web of Science ®Google Scholar
• Becker A. Clinical Evidence with Montelukast in the Management of Chronic Childhood Asthma. rugs 2000; 59(Suppl. 1)29–34
   Google Scholar
• Knorr B., Noonan G., McBurney J., Shingo S., Nguyen H.H., Reiss T.F. Evaluation of Long-Term Effect of Montelukast in Adult (>15 years) and Pediatric (6-to-14 Years) Patients [Abstract]. Eur. Respir. J. 1999; 14(30)290S
   Google Scholar
• Knorr B., Matz J., Bernstein J.A., Nguyen H., Seidenberg B.C., Reiss T.F., Becker A. Montelukast for Chronic Asthma in 6- to 14-Year-Old Children: A Randomized, ouble-Blind Trial. Pediatric Montelukast Study Group. JAMA 1998; 279(15)1181–1186
   PubMed Web of Science ®Google Scholar
• Knorr B., Noonan G., McBurney J., Zhang J., Nguyen H., Shingo S., Seidenberg B., Reiss T.F. Evaluation of the Safety Profile of Montelukast (MK-0476) in Adult and Pediatric Patients (Aged 6 to 14 Years) [Abstract]. Eur. Respir. J. 1998; 12(28)274S
   Google Scholar
• Edelman J.M., Bronsky E.A., Grossman J., Kemp J.P., Ghannam A.F., DeLucca P.T., Gormley G.J., Pearlman D.S. Oral Montelukast Compared with Inhaled Salmeterol to Prevent Exercise-Induced Bronchoconstriction. A Randomized, ouble-Blind Trial. Exercise Study Group. Ann. Intern. Med. 2000; 132(2)97–104
   PubMedGoogle Scholar
• Villaran C., O’Neill S.J., Helbling A., van Noord J.A., Lee T.H., Chuchalin A.G., Langley S.J., Gunawardena K.A., Suskovic S., Laurenzi M., Jasan J., Menten J., Leff J.A. Montelukast Versus Salmeterol in Patients with Asthma and Exercise-Induced Bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. J. Allergy Clin. Immunol. 1999; 104(3 pt. 1)547–553
   PubMedGoogle Scholar
• Kemp J.P., Dockhorn R.J., Shapiro G.G., Nguyen H.H., Reiss T.F., Seidenberg B.C., Knorr B. Montelukast Once Daily Inhibits Exercise-Induced Bronchoconstriction in 6- to 14-Year-Old Children with Asthma. J. Pediatr. 1998; 133(3)424–428
   PubMed Web of Science ®Google Scholar
• Leff J.A., Busse W.W., Pearlman D., Bronsky E.A., Kemp J., Hendeles L., Dockhorn R., Kundu S., Zhang J., Seidenberg B.C., Reiss T.F. Montelukast, a Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced Bronchoconstriction. N. Engl. J. Med. 1998; 339(3)147–152
   PubMed Web of Science ®Google Scholar
• Nayak A.S., Anderson P., Charous B.L., Williams K., Simonson S. Equivalence of Adding Zafirlukast Versus Double-Dose Inhaled Corticosteroids in Asthmatic Patients Symptomatic on Low-Dose Inhaled Corticosteroids [Abstract]. J. Allergy Clin. Immunol. 1998; 101(1 pt. 2)S233
   Google Scholar
• Pauwels R.A., Lofdahl C.G., Postma D.S., Tattersfield A.E., O’Byrne P., Barnes P.J., Ullman A. Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N. Engl. J. Med. 1997; 337(20)1405–1411
   PubMed Web of Science ®Google Scholar
• Evans D.J., Taylor D.A., Zetterstrom O., Chung K.F., O’Connor B.J., Barnes P.J. A Comparison of Low-Dose Inhaled Budesonide Plus Theophylline and High-Dose Inhaled Budesonide for Moderate Asthma. N. Engl. J. Med. 1997; 337(20)1412–1418
   PubMed Web of Science ®Google Scholar
• Reiss T.F., Chervinsky P., Dockhorn R.J., Shingo S., Seidenberg B., Edwards T.B. Montelukast, a Once-Daily Leukotriene Receptor Antagonist, in the Treatment of Chronic Asthma: a Multicenter, andomized, ouble-Blind Trial. Montelukast Clinical Research Study Group. Arch. Intern. Med. 1998; 158(11)1213–1220
   PubMed Web of Science ®Google Scholar
• Reiss T.F., Sorkness C.A., Stricker W., Botto A., Busse W.W., Kundu S., Zhang J. Effects of Montelukast (MK-0476); a Potent Cysteinyl Leukotriene Receptor Antagonist, on Bronchodilation in Asthmatic Subjects Treated With and Without Inhaled Corticosteroids. Thorax 1997; 52(1)45–48
   PubMed Web of Science ®Google Scholar
• Richter D., Tjesic-Drinkovic D., Kelecic J., Voskresensky-Baricic T., Kukac L. Substituting Montelukast for Inhaled Corticosteroids in Children with Mild Persistent Asthma [Abstract]. Eur. Respir. J. 2000; 16(31)306S
   Google Scholar
• Markson L.E., Vollmer W.M., Fitterman L., O’Connor E., Narayanan S., Berger M., Buist A.S. Insight into Patient Dissatisfaction with Asthma Treatment. Arch. Int. Med. 2001; 161: 379–384
   PubMed Web of Science ®Google Scholar